- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Origin House announced a binding term sheet with AltMed to alter its agreement in order to raise its equity position in AltMed.
Origin House (CSE:OH) announced a binding term sheet with Alternative Medical Enterprises (AltMed) to alter its agreement in order to raise its equity position in AltMed.
As quoted in the press release:
Origin House a leading North American cannabis products and brands company, today announced that it has signed a binding term sheet (the “Agreement”) with Alternative Medical Enterprises, LLC (“AltMed”) to convert the Company’s 3.5 [percent] royalty interest on the sale of AltMed’s MÜV branded products (“MÜV”) into a combination of cash and 125 units of AltMed’s equity raising Origin House’s aggregate equity position in AltMed to 5.1 [percent].
Marc Lustig, Chairman and CEO of Origin House said, “AltMed has established itself as a successful cannabis business in the key markets of Florida and Arizona. Based on our discussions with AltMed, we believe eliminating the royalty will facilitate the multi-jurisdictional expansion of MÜV products and also furthers our strategic aim of converting non-core assets like the MÜV royalty.”
Transaction Details:
Origin House currently owns a 4.8 [percent] equity interest in AltMed and a 3.5 [percent] gross product royalty on the sale of certain MÜV products. Pursuant to the Agreement, AltMed will issue 125 units to Origin House in addition to cash, as consideration for the Company’s royalty interest. Upon conversion of the royalty interest, Origin House will own an aggregate of 5.1 [percent] of AltMed. Based on the valuation ascribed to AltMed for the conversion of the royalty, this 5.1 [percent] equity position has an equity value of US$10.3 million. The anticipated closing date is on or before February 15, 2019.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.